Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Pseudomonas Aeruginosa Infections-Pipeline Review, H1 2015

Pseudomonas Aeruginosa Infections-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Pseudomonas Aeruginosa Infections-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Pseudomonas Aeruginosa Infections-Pipeline Review, H1 2015', provides an overview of the Pseudomonas Aeruginosa Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Pseudomonas Aeruginosa Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Pseudomonas Aeruginosa Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Pseudomonas Aeruginosa Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Pseudomonas Aeruginosa Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Pseudomonas Aeruginosa Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Pseudomonas Aeruginosa Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Pseudomonas Aeruginosa Infections Overview 11

Therapeutics Development 12

Pipeline Products for Pseudomonas Aeruginosa Infections-Overview 12

Pipeline Products for Pseudomonas Aeruginosa Infections-Comparative Analysis 13

Pseudomonas Aeruginosa Infections-Therapeutics under Development by Companies 14

Pseudomonas Aeruginosa Infections-Therapeutics under Investigation by Universities/Institutes 19

Pseudomonas Aeruginosa Infections-Pipeline Products Glance 21

Late Stage Products 21

Clinical Stage Products 22

Early Stage Products 23

Unknown Stage Products 24

Pseudomonas Aeruginosa Infections-Products under Development by Companies 25

Pseudomonas Aeruginosa Infections-Products under Investigation by Universities/Institutes 31

Pseudomonas Aeruginosa Infections-Companies Involved in Therapeutics Development 33

Achaogen Inc. 33

Adenium Biotech ApS 34

Aeolus Pharmaceuticals, Inc. 35

AlgiPharma AS 36

Allergan Plc 37

AmpliPhi Biosciences Corporation 38

AnGes MG, Inc. 39

Arch Biopartners, Inc. 40

Aridis Pharmaceuticals LLC 41

AstraZeneca Plc 42

Biolytics Pharma 43

ConjuGon, Inc. 44

CSA Biotechnologies LLC 45

F. Hoffmann-La Roche Ltd. 46

FOB Synthesis, Inc. 47

GlaxoSmithKline Plc 48

GlycoMimetics, Inc. 49

Helix BioMedix, Inc. 50

Insmed Incorporated 51

LegoChem Biosciences, Inc 52

Lytix Biopharma AS 53

MedImmune, LLC 54

Melinta Therapeutics, Inc 55

Microbiotix, Inc. 56

Northern Antibiotics Oy 57

Nosopharm SAS 58

Novabiotics Limited 59

Novan, Inc. 60

Omnia Molecular Ltd. 61

Pfizer Inc. 62

Pherecydes Pharma SA 63

Phico Therapeutics Limited 64

Phylogica Limited 65

Polyphor Ltd. 66

Procarta Biosystems Ltd 67

Sarepta Therapeutics, Inc. 68

Sealife PHARMA GMBH 69

Sequoia Sciences, Inc. 70

Shionogi & Co., Ltd. 71

Soligenix, Inc. 72

Spider Biotech 73

Syntiron LLC 74

Tetraphase Pharmaceuticals Inc. 75

Trana Discovery, Inc. 76

Valneva SE 77

Vaxdyn, S.L. 78

Zambon Company S.p.A. 79

Pseudomonas Aeruginosa Infections-Therapeutics Assessment 80

Assessment by Monotherapy Products 80

Assessment by Combination Products 81

Assessment by Target 82

Assessment by Mechanism of Action 84

Assessment by Route of Administration 86

Assessment by Molecule Type 88

Drug Profiles 90

(fosfomycin + tobramycin)-Drug Profile 90

AA-139-Drug Profile 91

ACHN-975 Prodrug-Drug Profile 92

Aerucin-Drug Profile 93

AG-30/5C-Drug Profile 94

amikacin liposomal-Drug Profile 95

AmpliPHAGE-001-Drug Profile 99

Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections-Drug Profile 101

Antisense Oligonucleotide for Drug Resistant Pseudomonas Aeruginosa Infections-Drug Profile 102

APT-1026-Drug Profile 103

AR-104-Drug Profile 105

Biologic for Pseudomonas Aeruginosa Infection-Drug Profile 106

BXN-112-Drug Profile 107

Cell Therapy for GBM and Pseudomonas Aeruginosa Infections-Drug Profile 108

Cephalosporin + Beta-Lactamase Inhibitor-Drug Profile 109

CSA-13-Drug Profile 110

dehydroleucodine-Drug Profile 111

Drug for Infectious Diseases-Drug Profile 112

Drug for Psuedomonas aeruginosa Respiratory Infections-Drug Profile 113

dusquetide-Drug Profile 114

FSI-1671-Drug Profile 116

FSI-1686-Drug Profile 117

G-10-Drug Profile 118

GMI-1051-Drug Profile 119

GN snare-Drug Profile 120

GN-4474-Drug Profile 121

HB-1345-Drug Profile 122

HT-05-Drug Profile 123

KBP-7963-Drug Profile 124

LCB-100200-Drug Profile 125

LTX-109-Drug Profile 126

MBX-2359-Drug Profile 128

MDN-0057-Drug Profile 129

Monoclonal Antibodies for Gram-Negative Bacterial Infections-Drug Profile 131

NAB-7061-Drug Profile 132

NAB-739-Drug Profile 134

NAB-741-Drug Profile 135

NBTI-5463-Drug Profile 136

NOSO-95300-Drug Profile 137

NP-432-Drug Profile 138

NVN-1000-Drug Profile 139

NVN-4428-Drug Profile 140

Oligomer G for Pseudomonas Aeruginosa Infectious-Drug Profile 141

Panaecin-Drug Profile 142

POL-7080 Follow-On-Drug Profile 143

PP-1131-Drug Profile 144

Pseudomonas aeruginosa vaccine-Drug Profile 146

Pseudomonas aeruginosa vaccine-Drug Profile 147

Pseudomonas aeruginosa vaccine-Drug Profile 148

Pseudomonas aeruginosa vaccine-Drug Profile 149

pseudomonas and VAP conjugate vaccine-Drug Profile 150

PT-3.1-Drug Profile 151

PT-3.33-Drug Profile 152

RX-05-Drug Profile 153

RXP-763-Drug Profile 154

RXP-766-Drug Profile 156

RXP-770-Drug Profile 158

RXP-792-Drug Profile 160

RXP-793-Drug Profile 161

RXP-808-Drug Profile 162

RXP-873-Drug Profile 163

S-649266-Drug Profile 164

SB-041-Drug Profile 165

Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections-Drug Profile 166

SLP-0901-Drug Profile 167

Small Molecule 2 to Inhibit Lectin B for Pseudomonas Aeruginosa Infections-Drug Profile 168

Small Molecule for Bacterial Infections-Drug Profile 169

Small Molecule for Gram-Negative Nosocomial Infections-Drug Profile 170

Small Molecule to Inhibit Lectin B for Pseudomonas Aeruginosa Infections-Drug Profile 171

Small Molecule to Inhibit Lectins for Pseudomonas Infections-Drug Profile 172

Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections-Drug Profile 173

Small Molecules for Bacterial Infections-Drug Profile 174

Small Molecules for Gram-Negative Bacterial Infections-Drug Profile 175

Small Molecules for Gram-Negative Bacterial Infections-Drug Profile 176

Small Molecules for Gram-Negative Bacterial Infections and Pseudomonas Aeruginosa Infections-Drug Profile 177

Small Molecules for Multi-Drug Resistant Bacterial Infections-Drug Profile 178

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections-Drug Profile 179

Small Molecules for Pseudomonas Aeruginosa Infection and Inflammation-Drug Profile 180

Small Molecules for Resistant Pseudomonas aeruginosa Infections-Drug Profile 181

Small Molecules to Inhibit LasB for Pseudomonas Aeruginosa Infections-Drug Profile 182

Small Molecules to Inhibit LasR Receptor for Lung Infections and Pseudomonas aeruginosa Infections-Drug Profile 183

Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections-Drug Profile 184

Small Molecules to Inhibit PqsD for Pseudomonas Aeruginosa Infections-Drug Profile 185

Small Molecules to Inhibit T3SS for Pseudomonas Aeruginosa Infections-Drug Profile 186

Small Molecules to Inhibit the Fatty Acid Synthesis for Pseudomonas Aeruginosa Infections-Drug Profile 187

Small Molecules to Inhibit Tryptophanyl-tRNA synthetase for Bacterial Infections-Drug Profile 188

Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease-Drug Profile 189

TP-433-Drug Profile 190

TP-559-Drug Profile 191

V-2L2MD-Drug Profile 192

VLA-43-Drug Profile 193

VXD-002-Drug Profile 195

ZP-044-Drug Profile 196

ZP-046-Drug Profile 197

Pseudomonas Aeruginosa Infections-Recent Pipeline Updates 198

Pseudomonas Aeruginosa Infections-Dormant Projects 215

Pseudomonas Aeruginosa Infections-Discontinued Products 218

Pseudomonas Aeruginosa Infections-Product Development Milestones 219

Featured News & Press Releases 219

Appendix 226

Methodology 226

Coverage 226

Secondary Research 226

Primary Research 226

Expert Panel Validation 226

Contact Us 226

Disclaimer 227

List of Tables

Number of Products under Development for Pseudomonas Aeruginosa Infections, H1 2015 18

Number of Products under Development for Pseudomonas Aeruginosa Infections-Comparative Analysis, H1 2015 19

Number of Products under Development by Companies, H1 2015 21

Number of Products under Development by Companies, H1 2015 (Contd..1) 22

Number of Products under Development by Companies, H1 2015 (Contd..2) 23

Number of Products under Development by Companies, H1 2015 (Contd..3) 24

Number of Products under Investigation by Universities/Institutes, H1 2015 26

Comparative Analysis by Late Stage Development, H1 2015 27

Comparative Analysis by Clinical Stage Development, H1 2015 28

Comparative Analysis by Early Stage Development, H1 2015 29

Comparative Analysis by Unknown Stage Development, H1 2015 30

Products under Development by Companies, H1 2015 31

Products under Development by Companies, H1 2015 (Contd..1) 32

Products under Development by Companies, H1 2015 (Contd..2) 33

Products under Development by Companies, H1 2015 (Contd..3) 34

Products under Development by Companies, H1 2015 (Contd..4) 35

Products under Development by Companies, H1 2015 (Contd..5) 36

Products under Investigation by Universities/Institutes, H1 2015 37

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 38

Pseudomonas Aeruginosa Infections-Pipeline by Achaogen Inc., H1 2015 39

Pseudomonas Aeruginosa Infections-Pipeline by Adenium Biotech ApS, H1 2015 40

Pseudomonas Aeruginosa Infections-Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015 41

Pseudomonas Aeruginosa Infections-Pipeline by AlgiPharma AS, H1 2015 42

Pseudomonas Aeruginosa Infections-Pipeline by Allergan Plc, H1 2015 43

Pseudomonas Aeruginosa Infections-Pipeline by AmpliPhi Biosciences Corporation, H1 2015 44

Pseudomonas Aeruginosa Infections-Pipeline by AnGes MG, Inc., H1 2015 45

Pseudomonas Aeruginosa Infections-Pipeline by Arch Biopartners, Inc., H1 2015 46

Pseudomonas Aeruginosa Infections-Pipeline by Aridis Pharmaceuticals LLC, H1 2015 47

Pseudomonas Aeruginosa Infections-Pipeline by AstraZeneca Plc, H1 2015 48

Pseudomonas Aeruginosa Infections-Pipeline by Biolytics Pharma, H1 2015 49

Pseudomonas Aeruginosa Infections-Pipeline by ConjuGon, Inc., H1 2015 50

Pseudomonas Aeruginosa Infections-Pipeline by CSA Biotechnologies LLC , H1 2015 51

Pseudomonas Aeruginosa Infections-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 52

Pseudomonas Aeruginosa Infections-Pipeline by FOB Synthesis, Inc., H1 2015 53

Pseudomonas Aeruginosa Infections-Pipeline by GlaxoSmithKline Plc, H1 2015 54

Pseudomonas Aeruginosa Infections-Pipeline by GlycoMimetics, Inc., H1 2015 55

Pseudomonas Aeruginosa Infections-Pipeline by Helix BioMedix, Inc., H1 2015 56

Pseudomonas Aeruginosa Infections-Pipeline by Insmed Incorporated, H1 2015 57

Pseudomonas Aeruginosa Infections-Pipeline by LegoChem Biosciences, Inc, H1 2015 58

Pseudomonas Aeruginosa Infections-Pipeline by Lytix Biopharma AS, H1 2015 59

Pseudomonas Aeruginosa Infections-Pipeline by MedImmune, LLC, H1 2015 60

Pseudomonas Aeruginosa Infections-Pipeline by Melinta Therapeutics, Inc, H1 2015 61

Pseudomonas Aeruginosa Infections-Pipeline by Microbiotix, Inc., H1 2015 62

Pseudomonas Aeruginosa Infections-Pipeline by Northern Antibiotics Oy, H1 2015 63

Pseudomonas Aeruginosa Infections-Pipeline by Nosopharm SAS, H1 2015 64

Pseudomonas Aeruginosa Infections-Pipeline by Novabiotics Limited, H1 2015 65

Pseudomonas Aeruginosa Infections-Pipeline by Novan, Inc., H1 2015 66

Pseudomonas Aeruginosa Infections-Pipeline by Omnia Molecular Ltd., H1 2015 67

Pseudomonas Aeruginosa Infections-Pipeline by Pfizer Inc., H1 2015 68

Pseudomonas Aeruginosa Infections-Pipeline by Pherecydes Pharma SA, H1 2015 69

Pseudomonas Aeruginosa Infections-Pipeline by Phico Therapeutics Limited, H1 2015 70

Pseudomonas Aeruginosa Infections-Pipeline by Phylogica Limited, H1 2015 71

Pseudomonas Aeruginosa Infections-Pipeline by Polyphor Ltd., H1 2015 72

Pseudomonas Aeruginosa Infections-Pipeline by Procarta Biosystems Ltd, H1 2015 73

Pseudomonas Aeruginosa Infections-Pipeline by Sarepta Therapeutics, Inc., H1 2015 74

Pseudomonas Aeruginosa Infections-Pipeline by Sealife PHARMA GMBH, H1 2015 75

Pseudomonas Aeruginosa Infections-Pipeline by Sequoia Sciences, Inc., H1 2015 76

Pseudomonas Aeruginosa Infections-Pipeline by Shionogi & Co., Ltd., H1 2015 77

Pseudomonas Aeruginosa Infections-Pipeline by Soligenix, Inc., H1 2015 78

Pseudomonas Aeruginosa Infections-Pipeline by Spider Biotech, H1 2015 79

Pseudomonas Aeruginosa Infections-Pipeline by Syntiron LLC, H1 2015 80

Pseudomonas Aeruginosa Infections-Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 81

Pseudomonas Aeruginosa Infections-Pipeline by Trana Discovery, Inc., H1 2015 82

Pseudomonas Aeruginosa Infections-Pipeline by Valneva SE, H1 2015 83

Pseudomonas Aeruginosa Infections-Pipeline by Vaxdyn, S.L., H1 2015 84

Pseudomonas Aeruginosa Infections-Pipeline by Zambon Company S.p.A., H1 2015 85

Assessment by Monotherapy Products, H1 2015 86

Assessment by Combination Products, H1 2015 87

Number of Products by Stage and Target, H1 2015 89

Number of Products by Stage and Mechanism of Action, H1 2015 91

Number of Products by Stage and Route of Administration, H1 2015 93

Number of Products by Stage and Molecule Type, H1 2015 95

Pseudomonas Aeruginosa Infections Therapeutics-Recent Pipeline Updates, H1 2015 204

Pseudomonas Aeruginosa Infections-Dormant Projects, H1 2015 221

Pseudomonas Aeruginosa Infections-Dormant Projects (Contd..1), H1 2015 222

Pseudomonas Aeruginosa Infections-Dormant Projects (Contd..2), H1 2015 223

Pseudomonas Aeruginosa Infections-Discontinued Products, H1 2015 224

List of Figures

Number of Products under Development for Pseudomonas Aeruginosa Infections, H1 2015 18

Number of Products under Development for Pseudomonas Aeruginosa Infections-Comparative Analysis, H1 2015 19

Number of Products under Development by Companies, H1 2015 20

Number of Products under Investigation by Universities/Institutes, H1 2015 25

Comparative Analysis by Late Stage Development, H1 2015 27

Comparative Analysis by Clinical Stage Development, H1 2015 28

Comparative Analysis by Early Stage Products, H1 2015 29

Assessment by Monotherapy Products, H1 2015 86

Assessment by Combination Products, H1 2015 87

Number of Products by Top 10 Targets, H1 2015 88

Number of Products by Stage and Top 10 Targets, H1 2015 88

Number of Products by Top 10 Mechanism of Actions, H1 2015 90

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 90

Number of Products by Top 10 Routes of Administration, H1 2015 92

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 92

Number of Products by Top 10 Molecule Types, H1 2015 94

Number of Products by Stage and Top 10 Molecule Types, H1 2015 94

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Achaogen Inc.

Adenium Biotech ApS

Aeolus Pharmaceuticals, Inc.

AlgiPharma AS

Allergan Plc

AmpliPhi Biosciences Corporation

AnGes MG, Inc.

Arch Biopartners, Inc.

Aridis Pharmaceuticals LLC

AstraZeneca Plc

Biolytics Pharma

ConjuGon, Inc.

CSA Biotechnologies LLC

F. Hoffmann-La Roche Ltd.

FOB Synthesis, Inc.

GlaxoSmithKline Plc

GlycoMimetics, Inc.

Helix BioMedix, Inc.

Insmed Incorporated

LegoChem Biosciences, Inc

Lytix Biopharma AS

MedImmune, LLC

Melinta Therapeutics, Inc

Microbiotix, Inc.

Northern Antibiotics Oy

Nosopharm SAS

Novabiotics Limited

Novan, Inc.

Omnia Molecular Ltd.

Pfizer Inc.

Pherecydes Pharma SA

Phico Therapeutics Limited

Phylogica Limited

Polyphor Ltd.

Procarta Biosystems Ltd

Sarepta Therapeutics, Inc.

Sealife PHARMA GMBH

Sequoia Sciences, Inc.

Shionogi & Co., Ltd.

Soligenix, Inc.

Spider Biotech

Syntiron LLC

Tetraphase Pharmaceuticals Inc.

Trana Discovery, Inc.

Valneva SE

Vaxdyn, S.L.

Zambon Company S.p.A.

Pseudomonas Aeruginosa Infections Therapeutic Products under Development, Key Players in Pseudomonas Aeruginosa Infections Therapeutics, Pseudomonas Aeruginosa Infections Pipeline Overview, Pseudomonas Aeruginosa Infections Pipeline, Pseudomonas Aeruginosa Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com